Skip to Main Content

Advertisement

Skip Nav Destination

Abstract P242: Preclinical efficacy landscape of the pan-CLK/DYRK inhibitor Cirtuvivint (SM08502)

Mol Cancer Ther (2021) 20 (12_Supplement): P242.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal